Byoung-gie G. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 290 publications

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Journal: Lancet (London, England)

Published: February 10, 2026

Risk Factors Affecting Clinical Outcomes of Low-risk Early-stage Human Papillomavirus-Associated Endocervical Adenocarcinoma Treated by Surgery Alone: Application of Silva Pattern.

Risk Factors Affecting Clinical Outcomes of Low-risk Early-stage Human Papillomavirus-Associated Endocervical Adenocarcinoma Treated by Surgery Alone: Application of Silva Pattern.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: October 09, 2025

Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.

Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.

Journal: Gynecologic oncology

Published: September 24, 2025

Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.

Erratum: The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization.

Journal: Journal of gynecologic oncology

Published: September 19, 2025

Survival implications of computed tomography-derived muscle mass changes in patients with epithelial ovarian cancer undergoing bowel surgery.

Survival implications of computed tomography-derived muscle mass changes in patients with epithelial ovarian cancer undergoing bowel surgery.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 09, 2025

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: August 21, 2025

Improved Prognostic Stratification with the FIGO 2023 Staging System in Endometrial Cancer: Real-World Validation in 2969 Patients.

Improved Prognostic Stratification with the FIGO 2023 Staging System in Endometrial Cancer: Real-World Validation in 2969 Patients.

Journal: Cancers

Published: August 04, 2025

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: August 04, 2025

Diagnostic performance of cervical cytology in HPV-independent cervical cancer: a comparative analysis with HPV-associated cases.

Diagnostic performance of cervical cytology in HPV-independent cervical cancer: a comparative analysis with HPV-associated cases.

Journal: Journal of gynecologic oncology

Published: August 04, 2025

Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).

Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).

Journal: Journal of gynecologic oncology

Published: July 16, 2025

The decision for adjuvant therapy for early-stage high-risk endometrial cancer is in dilemma.

The decision for adjuvant therapy for early-stage high-risk endometrial cancer is in dilemma.

Journal: Taiwanese journal of obstetrics & gynecology

Published: May 19, 2025

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: April 16, 2025

Showing 1-12 of 290

Last Updated: 09/26/2026